A 107-yr-old witness to the Tulsa Race Massacre just gave a powerful testimony to Congress

One hundred years ago, the Greenwood district of Tulsa, Oklahoma was a bustling Mecca of Black-owned businesses and a community where Black Americans thrived. It was known colloquially as "Black Wall Street," and was an anomaly in a state where the KKK actively worked to keep Black people oppressed.

On May 31 and June 1, 1921, it all changed. An alleged assault attempt by a young Black man against a young white woman (which never amounted to anything, as all charges were dropped) sparked protests, violence, and ultimately, a massacre by white mobs who murdered, looted, and set fire to Black Wall Street. More than 1200 homes were destroyed, churches were burned, and businesses wiped out. Thousands of white people descended on Greenwood and obliterated 35 city blocks in 24 hours, causing irreparable financial damage in addition to the emotional toll of the massacre.

The death count has never been verified. One newspaper initially only reported that two white people were killed in the "race riot." Current estimates put the number killed at around 300, almost all of them Black residents. Thousands of those left behind had to live in tents and try to pick up the pieces of their lives, literally and figuratively.


But many Americans never learn this history. It has rarely been taught in schools, even in Oklahoma, partially because much of the documentation of the massacre was covered up. A 1997 commission organized by the city examined documents and interviewed survivors to piece together what really happened on those days, and they released a report on their findings in 2001. Of their many notable findings, the commission determined that white Tulsa officials participated in the violence, even providing the white mob with firearms and ammunition to terrorize the Black residents.

The massacre of Tulsa's "Black Wall Street" www.youtube.com

The survivors that the city interviewed are gone now, but there are still a few people left who witnessed the massacre.

107-year-old Viola Fletcher, the oldest living survivor, testified this week before the House Judiciary Subcommittee on Constitution, Civil Rights, and Civil Liberties, asking the U.S. to formally "acknowledge what happened in Tulsa in 1921" on its centennial. Her testimony was powerful.

"I still see Black men being shot, Black bodies lying in the street. I still smell smoke and see fire," Fletcher told lawmakers. "I still see Black businesses being burned. I still hear airplanes flying overhead. I hear the screams. I have lived through the massacre every day."

"I am 107 years old and have never seen justice," she said. "I pray that one day I will. I have been blessed with a long life -- and have seen the best and worst of this country. I think about the terror inflicted upon Black people in this country every day."

Watch her powerful 7-minute testimony:

POWERFUL: Oldest living survivor of Tulsa race massacre testifies in front of House www.youtube.com


Another survivor, 106-year-old Lessie Benningfield Randle also testified about what she witnessed when she was six.

"They burned houses and businesses. They just took what they wanted out of the buildings then they burned them," she said." They murdered people. We were told they just dumped the dead bodies into the river. I remember running outside of our house. I ran past dead bodies. It wasn't a pretty sight. I still see it today in my mindβ€”100 years later."

The remaining survivors have called for reparations, citing the inability of the community to rebuild following the massacre, especially in light of the Jim Crow laws and racist economic policies that followed.

Many Americans tend to think of the history of blatant, violent, government-sanctioned racism as something in the distant past, but there are still people alive today who remember this massacre that took place in 1921. And that year was a mere 50 years after the start of the Civil War, which means many Black Americans living in the South at that time had been born into slavery. That history is simply not that far away.

All three of the testimonies from survivors of the Tulsa-Greenwood Race Massacre are powerful. You can watch the full House Judiciary hearing here:

Continuing Injustice: The Centennial of the Tulsa-Greenwood Race Massacre www.youtube.com

via Sasssy Gran / TikTok

A 95-year-old-grandmother has become a sensation on TikTok, a platform that's most popular among the Gen Z set. Doris, also known as Sassy Gran, has become popular for her incredibly bold and refreshingly honest personality.

She's had a tough life which has given her a special edge that you don't find with most nonagenarians. There's also her elegant couture to show the young kids what real class looks like.

Doris was made famous by her grandson Gio who clearly loves going out to dinner with his grandmother and hearing her stories and advice.

Keep Reading Show less
via Sasssy Gran / TikTok

A 95-year-old-grandmother has become a sensation on TikTok, a platform that's most popular among the Gen Z set. Doris, also known as Sassy Gran, has become popular for her incredibly bold and refreshingly honest personality.

She's had a tough life which has given her a special edge that you don't find with most nonagenarians. There's also her elegant couture to show the young kids what real class looks like.

Doris was made famous by her grandson Gio who clearly loves going out to dinner with his grandmother and hearing her stories and advice.

Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer β€” most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving β€” and for longer β€” than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval β€” an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases β€” something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."